The Journal of Immunology · 2006 · 487 citations · 40 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunoregulationTumor ImmunologyCancer Cell-cell CommunicationCancer ImmunotherapyCytokines In Tumor ImmunityExtracellular Vesicle SignalingCyclin RegulationEx Vivo DeliveryEx Vivo ModelsExosome-mediated Immune SuppressionExosomesExosomes In CancerImmune Modulation By Extracellular VesiclesTumor-derived Exosomes
Many tumor cells shed specialized membrane vesicles known as exosomes. In this study, we show that pretreatment of mice with exosomes produced by TS/A or 4T.1 murine mammary tumor cells resulted in accelerated growth of implanted tumor cells in both syngeneic BALB/c mice and nude mice. As implanted TS/A tumor cells grew more rapidly in mice that had been depleted of NK cells, we analyzed the effects of the tumor-derived exosomes on NK cells. The tumor-derived exosomes inhibit NK cell cytotoxic activity ex vivo and in vitro as demonstrated by chromium release assays. The treatment of mice with TS/A tumor exosomes also led to a reduction in the percentages of NK cells, as determined by FACS analysis, in the lungs and spleens. Key features of NK cell activity were inhibited, including release of perforin but not granzyme B, as well as the expression of cyclin D3 and activation of the Jak3-mediated pathways. Human tumor cell lines also were found to produce exosomes that were capable of inhibiting IL-2-stimulated NK cell proliferation. Exosomes produced by dendritic cells or B cells did not. The presentation of tumor Ags by exosomes is under consideration as a cancer vaccine strategy; however, we found that pretreatment of mice with tumor exosomes blunted the protective effect of syngeneic dendritic cells pulsed ex vivo with tumor exosomes. We propose that tumor exosomes contribute to the growth of tumors by blocking IL-2-mediated activation of NK cells and their cytotoxic response to tumor cells.
40
David Kägi, Birgit Ledermann, Kurt Bürki et al. · Nature · 1994 · 1.8K citations
Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming
Joseph Wolfers, Anne Lozier, Graça Raposo et al. · Nature Medicine · 2001 · 1.6K citations
Life Sciences, Immunology, Oncology +16
Cells release prions in association with exosomes
Benoît Février, Didier Vilette, Fabienne Archer et al. · Proceedings of the National Academy of Sciences · 2004 · 983 citations · Full text
Indirect activation of naïve CD4+ T cells by dendritic cell–derived exosomes
Clotilde Théry, Livine Duban, Élodie Segura et al. · Nature Immunology · 2002 · 949 citations